vorasidenib (Servier)
Jump to navigation
Jump to search
Indications
- investigational treatment of gliomas with mutations in isocitrate dehydrogenase-1 & isocitrate dehydrogenase-2 (IDH1, IDH2)
* improves progression-free survival 28 months vs 11 months
Dosage
- oral administration
Adverse effects
- 23% vs 14%
- increased serum ALT 10%
Laboratory
More general terms
Additional terms
References
- ↑ Osterwell N Oral Drug for Brain Tumor Could Change Treatment Landscape Medscape. June 4, 2023 https://www.medscape.com/viewarticle/992745
Mellinghoff IK, van den Bent MJ, Blumenthal DT et al Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023. June 4 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37272516 https://www.nejm.org/doi/10.1056/NEJMoa2304194